An in silico analysis of early SARS-CoV-2 variant B.1.1.529 (Omicron) genomic sequences and their epidemiological correlates

Data collection

Sequence homology of Omicron (BA.1) with WT strains

Compared to the current list of global VOCs/VOIs (as per WHO) Omicron showed more sequence variation, more specifically in the spike protein (n21563-25384: 1-1273aa) including RBM (n22869-23089: 438-508aa), where the variations were most prominent (Table S1). The homology of the Omicron to the reference strain (hCoV-19/Wuhan/WIV04/2019) for the spike protein sequence varied from 96.23 to 97.8% (28-48 mutations) in the analyzed sequences (Fig. 1).

• Download figure
• Open in new tab

Figure 1 3-D structure of Omicron (BA.1) spike glycoprotein in interaction of human ACE2 showing key amino acid substitutions.

(Data source: The figure has been generated from the genomic sequences of Omicron using CoVsurver app from Gisaid.org.)

Sequence homology of Omicron (BA.1) with existing SARS-CoV-2 VOCs/VOIs

The analysis of genomic and protein sequence homology of Omicron with the reference strain and current global VOCs/VOIs (as per WHO) showed the highest similarity of Omicron with the Alpha variant for the complete sequence as well as RBM, however, the highest similarity for the complete nucleotide and protein sequences for the spike protein were noted with Beta and Delta variants, respectively (Table S1).

Mutational analysis

The multiple clusters of closely spaced mutations were noted across the sequence, which were most densely placed in the spike protein region, particularly in its S1 subunit, including the host receptor-binding motif (RBM) (Fig. 2, Table 2). Many of the mutations in Omicron are common with the current global VOCs/VOIs (Fig. 3). Table 1 provides a list of the mutations in Omicron (BA.1) (present in at least 75% of sequences) and their functional characteristics based on the existing literature evidence. Based on the available evidence these mutations in pango-lineage BA.1 can be broadly categorized into four major groups: 1. Host receptor binding (10), 2. Host-adaptibility (3), 3. Immune escape (20), and 4. Virus replication (18) (Table 1).

• Download figure
• Open in new tab

Figure 2 The mutational landscape in SARS-CoV-2 variant B.1.1.529 (Omicron, sublineage: BA.1).

Abbreviations: RBD— receptor binding domain, RBM—receptor binding motif, ORF—open reading frame.

• Download figure
• Open in new tab

Figure 3 Lineage comparison between Omicron and other global variants of concerns/interest. Showing the mutations with > 75% prevalence in at least one lineage.

(Data source: The figure has been generated from outbreak.info, based on the SARS-CoV-2 genomic sequences uploaded in GISAID until 2021-12-6.)

The analysis of the mutations present at the RBD using deep mutational scanning pipeline by Starr et al, 2020 reflected prominent ACE2-binding affinity and protein expression changes (Table 2). Notably, mutations decresing the ACE2-binding affinity and protein expression were found significantly greater in number.

Epidemiological correlates

A total (N) of 4224 SARS-CoV-2 genomic sequences (NDelta = 999, NOmicron = 2937, and NOthers = 288) were uploaded on GISAID from SA in the period of study. For the complete duration of the study Delta correlated negatively with the new COVID-19 cases (r=-0.567, p=0.004, 95% CI=-0.79 to - 0.21), however positively with the new deaths (r=0.38, p=0.065, 95% CI= -0.025 to 0.68). The differential analysis of the SARS-CoV-2 genomic sequences from SA prior and after emrgence of the first case of Omicron (dated 2021-11-05, EPI_ISL_7456440) reflected sharp change in the dominance of the variant from Delta to Omicron (Fig. 4). An inverse correlation of Omicron with Delta variant was noted (r=-0.99, p< .001, 95% CI: -0.99 to -0.97) in the period of study. There has been a steep rise in the new COVID-19 cases in parrallel with the increase in proportion of Omicron since the first case of Omicron (74-100% of total genomic sequences after 15-17^th Nov, 2021), however, no parrallel increase has been observed in the death cases, which otherwise showed a reverse trend (r=-0.04, p>0.05, 95% CI =-0.52 to 0.58) (Fig. 4).

• Download figure
• Open in new tab

Figure 4 Epidemiological correlates of Omicron and Delta variants genomic sequences reported on GISAID from South Africa for the period of 1^st Oct-10^th Dec, 2021.

The proportion of Delta and Omicron variants in the total SARS-CoV-2 genomic sequences were correlated with the new COVID-19 cases and deaths in the period of study (3-day sum of each variable). A sharp change in the dominance from Delta to Omicron is observable since the first case (5^th Nov, 2021). The rise of Omicron cases has parrelled with the rise in the new COVID-19 cases. In comparison, the Delta variant is showing a fall in the same time period. Notably, there has been no increase in the number of deaths post emergence of Omicron. (Data source: gisaid.org and worldometer.info.)

Sequence variation with WT strains and existing SARS-CoV-2 VOCs/VOIs

Our analyses showed that Omicron has significantly greater variantions than current VOCs and VOIs in comparisons with the wild type strains (Wuhan strain and B.1). The sequence variation was greatest in the spike protein region, more particularly in the receptor-binding motif (RBM). Among the existing VOCs and VOIs, the highest homology of the complete sequence and RBM (nucleotide as well as protein) of Omicron was observed with Alpha variant (Table S1). Interestingly, similar to Alpha variant S-gene target failure (SGTF) in PCR based detection is proving a sensitive method for the detection of Omicron in the clinical samples²³.

As Omicron bears key mutations from multiple existing VOCs/VOIs, with approximate sequence homology variation, rather than a direct descendency, the multiple recombination events between the variants inside the hosts can be a more plausible explanation for its origin. Notably, compared with the WT strains, Omicron has significantly higher sequence variation than existing VOCs/VOIs, more specifically in spike protein region (Table S1). Further, in the spike protein region, the highest sequence variations is noted in RBM (Table S1).

It will be pertinent to explore the evolutionary mechanisms involved in accumulation of such a large number of mutations in Omicron. The speculations have also been raised that the long term persistence of SARS-CoV-2 infection in an immunocompromised subject can be a probable mechanism behind the Omicron origin. Existing literature^24–27 supports strong plausibility of this mechanism. Avanzato et al²⁴ and Choi et al²⁶ reported case studies of persistence of infection and accumulation of novel mutations in SARS-CoV-2 spike gene and RBD in a chronically ill and immunocompromised COVID-19 patients. Another such case has been recently reported by Karim et al²⁵. Authors documented long persistence of SARS-CoV-2 infection (more than six month) in a patient with advanced HIV and antiretroviral treatment failure. Through whole genome sequencing for SARS-CoV-2, performed at multiple time-points from the patient samples, authors demonstrated early emergence of the E484K substitution followed by N501Y, K417T, and multiple others mutation (including some novel mutations) in the spike gene and RBD. Increase in the genomic diversity reflecting intra-host evolution of SARS-CoV-2 during prolonged infection was also noted in a recent cohort study by Voloch et al²⁷.

Predicted effect on virus-host interactions

The new variant has accumulated multiple closely spaced mutations at receptor-binding motif (RBM) with ACE2, specifically a cluster of mutations have appeared at 477-501aa (Fig. 2). Notably, it has many of the mutations common with the earlier variants of concern (Fig. 3), many of which have been shown to enhance RBD:ACE2 binding in comparison to the WT strain²⁸, as has also been reflected in our analysis (Table 1-2). The selective mutations which are either present at or in the vicinity of the RBM (N440K, S477N, T478K, and N501Y) in majority of the Omicron sequences are believed to stabilize binding with ACE2 (Table 2). D614G, a key mutation characteristically present in all B.1 descendents²⁸, is known to stabilize the trimeric structure and create a more open conformation of the RBD allowing a stronger binding with ACE2²⁸.

In paradox, our analysis shows that the majority of the novel or rare spike mutations (<0.2% prevalence in the total sequenced samples, Table 1) in Omicron may have deleterious effect on the host interactions owing to their presence at the constrained RBD regions in terms of ACE2 binding (10/15) and/or RBD expression (8/15) (Table 2). Notably, most of the spike mutations which predicted a favorable effect on ACE2 binding or RBD expression or both are present in current VOCs, primarily Delta (T478K), and Alpha (N501Y), Beta (K417N) variants. Further, a set of mutations in Omicron which are present inside (P681H) or in vicinity (D614G, H655Y) of the furin cleavage site (FCS) of SARS-CoV-2 spike protein — a small stretch of peptide (PRRAR) inserted at the intersection of spike segments S1 and S2 (681–685 aa residues)— can enhance proteolytic cleavage of spike protein by a host protease-furin, which is said to improve its fusion to the host-cell membrane²⁹. P681H is characteristically present in multiple VOCs/VOIs such as B.1.1.7, P.1, Q.1 and B.1.621 lineage variants³⁰. A mutation at the same location P681R has been present in Delta variant and its emerging sub-lineages³¹. The characterization of the individual mutations present on RBM gives a speculation that Omicron may not have more efficient interactions with the host than existing VOCs/VOIs, more specifically Delta. A further assessment of the allosteric influence and dynamic interactions of the mutations present at RBD and other regions of spike protein, and examining in in situ/vivo studies will be necessary to understand their exact impact on host-receptor binding and its clinical correlates. The clinical data on severity of the illness in Omicron is currently very limited, although the evaluation of early cases has indicated a milder illness compared to the existing VOCs³².

Viral replication

Many of the mutations, especially in the non-spike regions, are linked with viral oligomerization and synthesis and packaging of the ribonucleic acid core (Table 1) and it is likely that they may have a role in replication of the virus inside the host cells³³. Particular to notice has been NSP12 P323L, a mutation present in RNA-dependent RNA polymerase (RdRp) coding region (Fig. 1, Table 1). Of note this has been a frequently observed mutation in the earlier variants (96.69%) (Table 1). However, whether these mutations will have a positive or a negative impact on the viral replication is little understood yet. Interestingly, the results of a preliminary study³⁴ which employed ex-vivo cultures of Omicron isolated from the respiratory tract of the infected patients, and compared that with WT and Delta variant strains. The authors observed that after 24 hours of incubation Omicron replicated 70 times faster than WT and Delta variant strains in the human bronchus. In contrast, it replicated less efficiently (>10 times lower) in the human lung tissue than WT strain, and also lower than Delta variant.

Immune escape

Majority of the spike mutations (18/32) in Omicron have occurred at the known antibody recognition sites (Table 1). Existing studies have established role of these mutations in immune escape against convalescent sera, vaccine acquired antibodies, and therapeutically used monoclonal antibodies (Table 1). The emerging preliminary evidence from in situ studies indicate potential immune escape by Omicron against convalescent sera, vaccine acquired antibodies, and therapeutically used monoclonal antibodies ^23,35,36. Interestingly, Omicron contains K417N and E484A, which are present in multiple existing variants, and are believed to contribute to immune escape²⁸. Of note, K417 locus is a known epitope for CB26—a therapeutically used monoclonal antibody in COVID-19²⁸. A larger number of mutations in Omicron spike protein, more specifically in RBD may be an evolutionary gain in this variant providing it higher immune escape. A support for this notion comes from a recent study by Nabel et al³⁷ who demonstrated that SARS-CoV-2 pseudotypes containing up to seven mutations, as opposed to the one to three found in earlier variants of concern, are more resistant to neutralization by therapeutic antibodies and serum from vaccine recipients.

A non-spike mutation (N) P13L present in Omicron (Table 1) is shown to cause complete loss of recognition by epitope-specific (B*27:05-restricted CD8+ nucleocapsid epitope QRNAPRITF9-17) T cells in a recent cell-line based in situ study²², however, no such evidence in human samples are currently available. In a recent preliminary study Redd et al examined peripheral blood mononuclear cell (PBMC) samples from PCR-confirmed, recovered/ convalescent COVID-19 cases (n=30) for their anti-SARS-CoV-2 CD8+ T-cell responses with Omicron. Authors noted that only one low-prevalence (found in 7%) epitope (GVYFASTEK, restricted to HLA*A03:01 and HLA*A11:01) from the spike protein (T95I) region was mutated in Omicron³⁸. Presence of these mutations raises concerns about escaping T cell immunity by Omicron³⁹ and hence are required to be explored in detail.

Currently in situ/vivo studies are scarce which have examined Omicron response against current COVID-19 vaccines in use, although, emerging preliminary evidence is supporting the prediction of immune escape for this variant^23,35,36,40. Cele et al²³ tested the ability of plasma from 14 BNT162b2 vaccinated study participants to neutralize Omicron versus WT D614G virus in a live virus neutralization assay.The authors observed that Omicron showed a 41-fold decline in FRNT50 Geometric mean titer (GMT) compared to WT D614G virus in the subjects without previous infection (6/14). Interestingly, those with previous infection showed relatively higher neutralization titers with Omicron (6/14), which indicated that the previous infection, followed by vaccination or booster may increase the levels of neutralization and protection from severe disease in cases of Omicron infection.

Epidemiological correlates: Omicron vs. Delta variants

The analysis of the SARS-CoV-2 genomic sequences from SA indicates the Omicron has gained an advantage in terms of transmissibility over Delta variant (Fig. 4). A third COVID-19 wave driven by Delta variant has recently occurred in SA⁴¹ hence current epidemiological characteristics of Delta and newly emerged variant in the local population should be analyzed in this backdrop. Our analyses showed that before the arrival of Omicron, Delta variant was dominant locally, on the contrary, at present majority of the new sequences are from Omicron (Omicron vs. Delta: r=-0.99, p< .001, 95% CI: -0.99 to -0.97) (Fig. 4). The steep rise in the new COVID-19 cases in SA are seem to be driven by Omicron, in contrast, Delta variant linked cases are seeing a decline (Fig. 4). The rapid rise in the new COVID-19 cases linked with the emergence of a new SARS-CoV-2 variant is strongly indicating the commencement of a new COVID-19 wave in SA⁴².

Further, the death, which is considered a strong indicator of the virulence/lethality, is showing a negative correlation (r=-0.04, p>0.05, 95% CI =-0.52 to 0.58) (Fig. 4) with rise in Omicron, however, it correlates positively with Delta variant in the period post-emergence (r=0.38, p=0.065, 95% CI= - 0.025 to 0.68) in the complete duration of the study. The pattern indicates that current deaths are primarily linked with Delta rather than Omicron.

At present, the studies are scarce which have examined transmissibility advantage for Omicron. A ∼2.4 (2.0-2.7) times higher transmissibility with Omicron compared to Delta variant in Gauteng, SA was indicated in a recent conference presentation by South African COVID-19 Modelling Consortium⁴³. Another preliminary estimate from UK has indicated that with Omicron risk of spreading infection to the members in a household is three times higher compared to Delta variant⁴⁴. Based on the current epidemiological patterns observed in SA, an epidemiological advantage to Omicron in comparison to Delta can be inferred in terms of transmissibility, however, our analysis has not indicated for increased lethality with Omicron compared to Delta and other variants currently circulating in SA population. However, it will be too early to assess the virulence/lethality with Omicron and a study of epidemiological patterns over a longer time period will be mandatory to develop a conclusive view on this.

It is noteworthy that the presence of an immunological barrier in the population imparted by recent COVID-19 wave mediated by Delta variant may be a likely reason for fall in new cases by this variant. A continuous fall in Delta cases is also noticeable in the period prior to emergence of Omicron (Fig. 4), which is further substantiating this notion. The data records show that a significant proportion of the local population in SA has been fully vaccinated by now (25.2%)⁴⁵. Notably, the high number of immune escape mutations in Delta has contributed to lowered efficacy of the vaccines, immunity from the natural infections, and therapeutically used antibodies²⁸. As Omicron contains much higher number of immune escape related mutations, including many shared with Delta (Fig. 3), it is likely that Omicron may have added potential for the vaccine breakthorugh infections and reinfections. Any supportive evidence in literature which examined immune escape capability of Omicron in epidemiological data is currently scarce, however, similar speculations have been presented by few other authors and the global health regulatory bodies^2,32,46. Interestingly, a higher risk of reinfections with Omicron has been indicated in a recent preprint article by Pulliam et al⁴⁷. The authors of this study have performed a retrospective analysis of routine epidemiological surveillance data to examine whether SARS-CoV-2 reinfection risk has changed through time in SA, in the context of the emergence of the consecutive variants: Beta, Delta, and Omicron. The authors noted that as compared to the first wave driven by WT strains subsequent waves by Beta and Delta variant had lower estimated hazard ratio for reinfection versus primary infection [relative hazard ratio for wave 2 vs. wave 1: 0.75 (CI95: 0.59-0.97); for wave 3 vs. wave 1:0.71 (CI95: 0.56-0.92)] in comparison to Omicron [Omicron surge vs. wave 1: 2.39 (95%CI: 1.88-3.11)].

Conclusion

In silico analysis of the viral genomic sequences suggest that the Omicron may have greater immune escape ability than the existing VOCs/VOIs including Delta. There are no clear indications that Omicron may have higher virulence/lethality than other, so far reported variants. Therefore, the higher ability for immune escape can be a likely reason for the recent surge in Omicron cases in SA.